Oncodesign Precision Medicine Société anonyme (FRA:ZR8)

Germany flag Germany · Delayed Price · Currency is EUR
0.3180
-0.0060 (-1.85%)
At close: Jun 26, 2026
Market Cap6.63M +25.8%
Revenue (ttm)1.81M +10.9%
Net Income5.48M
EPS0.30
Shares Out n/a
PE Ratio1.21
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open0.3110
Previous Close0.3240
Day's Range0.3110 - 0.3180
52-Week Range0.2570 - 0.7800
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJul 31, 2026

About FRA:ZR8

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1995
Employees 13
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ZR8

Financial Performance

Financial Statements